Stem cells are classified by potency. Pluripotent stem cells can form nearly any cell type in the body, while multipotent stem cells, including mesenchymal stromal cells, are restricted to a narrower set of lineages. The classification matters because marketing language and scientific definitions are not interchangeable.
A 2026 analysis of six commercial WJ products found low cell counts and viability with only rare viable MSCs; a 2021 study found no colony-forming MSCs in five cord products. That evidence is why a stem cell label on a finished cord-tissue allograft should be checked against lot-specific cell data rather than accepted as given.
For clinics searching for a stem cell supplier, the practical takeaway is to separate category language from product-level data. A supplier describing a product as a stem cell product is not itself evidence; a certificate of analysis, donor eligibility summary, and any cell-count or viability data behind the specific lot are the documents worth requesting before that language is used in any internal or buyer-facing material.
Buyers searching for a stem cell supplier should treat the phrase as a search category, not a product specification, and request lot-level data rather than relying on label language. These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.